This study examines trends in corticosteroid use for males with Duchenne muscular dystrophy by birth year, race/ethnicity, and knowledge of Duchenne muscular dystrophy family history. Firstborn males (n = 521) selected from a population-based surveillance system of Duchenne muscular dystrophy were analyzed using Kaplan Meier and regression methods. Comparing males born 1982 to 1986 with males born 1997 to 2001, steroid use increased from 54% to 72% and mean age at steroid initiation decreased from 8.2 to 7.1 years. Hispanics and non-Hispanic Black males used steroids less frequently and delayed initiation compared to white males. Compared to males without a Duchenne muscular dystrophy family history, males with known family history were half as likely to use steroids. Duration of steroid use increased over time and age at initiation decreased. Racial/ethnic disparities exist for steroid use and should be addressed to improve outcome and quality of life for boys with Duchenne muscular dystrophy.
BarberBJAndrewsJGLuZ. Oral corticosteroids and onset of cardiomyopathy in Duchenne muscular dystrophy. J Pediatr. 2013;163:1080–1084.e1
7.
DaftaryASCrisantiMKalraM. Effect of long-term steroids on cough efficiency and respiratory muscle strength in patients with Duchenne muscular dystrophy. Pediatrics. 2007;119:e320–e324.
8.
HenricsonEKAbreschRTCnaanA. The Cooperative International Neuromuscular Research Group Duchenne Natural History Study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rates of disease progression as measured by manual muscle testing and other commonly used clinical trial outcome measures. Muscle Nerve. 2013;48:55–67.
9.
HoudeSFilliatraultMFournierA. Deflazacort use in Duchenne muscular dystrophy: an 8-year follow-up. Pediatric Neurol. 2008;38:200–206.
10.
KingWMRuttencutterRNagarajaHN. Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology. 2007;68:1607–1613.
11.
MarkhamLWSpicerRLKhouryPR. Steroid therapy and cardiac function in Duchenne muscular dystrophy. Pediatr Cardiol. 2005;26:768–771.
12.
SchramGFournierALeducH. All-cause mortality and cardiovascular outcomes with prophylactic steroid therapy in Duchenne muscular dystrophy. J Am Col Card. 2013;61:948–954.
13.
MatthewsDJJamesKAMillerLA. Use of corticosteroids in a population-based cohort of boys with Duchenne and Becker muscular dystrophy. J Child Neurology. 2010;25:1319–1324.
14.
MoxleyRTPandyaSCiafaloniE. Change in natural history of Duchenne muscular dystrophy with long-term corticosteroid treatment: implications for Management. J Child Neurol. 2010;25:1116–1129.
15.
BushbyKFinkelRBirnkrantDJ. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol. 2010;9:77–93.
16.
GriggsRCHerrBERehaA. Corticosteroids in Duchenne muscular dystrophy: major variations in practice. Muscle Nerve. 2013;48:27–31.
17.
MillerLARomittiPACunniffC. The Muscular Dystrophy Surveillance Tracking and Research Network (MD STARnet): surveillance methodology. Birth Defects Res Part A. 2006;76:793–797.
18.
HoltzerCMeaneyJFAndrewsJ. Disparities in the diagnostic process of Duchenne and Becker muscular dystrophy. Genet Med. 2011;13:942–947.
19.
SmedleyBDStithAYNelsonAR. Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care. Washington, DC: National Academies Press; 2003.
20.
SmartJFSmartDW. Acceptance of disability and the Mexican American culture. Rehabil Counseling Bull. 1991;34:357–367.
21.
GarciaSBMendez PerezAOrtizAA. Mexican American mothers’ beliefs about disability: Implications for early childhood interventions. Remedial and Special Educ2000;21:90–120.
22.
Salas-ProvanceMBEricksonJGReedJ. Disabilities as viewed by four generations of one Hispanic family. Am J Speech Lang Pathol. 2002;11:151–162.
23.
Helderman-van den EndenATJMMadanKBreuningMH. An urgent need for a change in policy revealed by a study on prenatal testing for Duchenne muscular dystrophy. Eur J Hum Genet. 2013;21:21–26.
24.
MagriFGovoniAD'AngeloMG. Genotype and phenotype characterization in a large dystrophinopathic cohort with extended follow-up. J Neurol. 2011;258:1610–1623.
25.
MarkhamLWKinnettKWongBL. Corticosteroid treatment retards development of ventricular dysfunction in Duchenne muscular dystrophy. Neuromusc Disord. 2008;18:365–370.
26.
PassamanoLTagliaAPalladinoA. Improvement of survival in Duchenne muscular dystrophy: retrospective analysis of 835 patients. Acta Myol. 2012;31:121–125.
